Immunotherapy in NSCLC
Advertisement
The study included patients with advanced NSCLC with PD-L1 expression of at least 50% and no EGFR, ALK, or ROS abberations.
Investigators of a phase 2 study uncovered a biomarker that may be associated with major pathologic response in this setting.
The study investigators concluded that ivonescimab “might represent another treatment option in the first-line setting."
Researchers evaluated if there was a link between pretreatment systemic immune inflammation index levels and outcomes.
The therapy is currently under evaluation in phase 1 and phase 2 trials.
It is the "first and only neoadjuvant-only immuno-oncology therapy" to show a significant OS benefit in this setting.
The study is comparing ivonescimab plus platinum-based chemotherapy with tislelizumab plus platinum-based chemotherapy.
The study aims to confirm safety and efficacy findings from the phase 2 QUILT 3.055 trial.
Rilvegostomig showed a favorable safety profile and encouraging preliminary efficacy in NSCLC.
The subcutaneous injection is now approved for all adult indications of the intravenous formulation of atezolizumab
The trial is investigating nogapendekin alfa inbakicept-pmln in combination with immune checkpoint inhibitor therapy.
The therapy is now the “first and only subcutaneously administered PD-1 inhibitor," officials said in an announcement.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Patients with NSCLC, treated with an immunotherapy regimen, have a higher risk of pneumonitis with decreased lung volume.
An analysis of the CCTG BR.34 trial showed that bone metastasis correlated with worse outcomes in patients with NSCLC.
Detailed data from the trial will be presented at a medical meeting in 2025.
Researchers Analyze Olaparib, Pemetrexed as Maintenance Therapy Additions to Pembrolizumab for NSCLC
Pembrolizumab plus maintenance olaparib was not shown to improve survival in patients with metastatic nonsquamous NSCLC.
Durvalumab does not improve overall survival compared to chemotherapy when used as a first-line treatment for mNSCLC.
For patients with inoperable stage III NSCLC, ctDNA is associated with survival outcomes of consolidation immunotherapy.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.